SEEK: PepTcell Changes Name due to New Focus and Success

By Seek, PRNE
Tuesday, November 30, 2010

LONDON, December 1, 2010 - PepTcell, a leading UK privately-owned drug-discovery group, today
announced it is changing its name to SEEK.

Gregory Stoloff, Chief Executive Officer, explains: "SEEK has
a significant number of potential blockbuster assets in different legal
entities and we wanted to give them a common identity and purpose. Announcing
a simple and uniting group brand name, SEEK, reflects our efforts to 'seek a
cure' in a number of major disease areas."

SEEK has a leading innovative mid-to-late stage portfolio of
breakthrough treatments. Entering Phase III trials are a first-in-class cough
suppressant, with a clinically-proven efficacy and safety profile, and a
small-molecule drug for inflammatory flare, with a clinically-proven safety
analgesic profile. In the area of vaccination, SEEK has made significant
progress with a universal flu vaccine - intended to be effective against all
strains of flu virus, eliminating the need for annual flu vaccinations - and
an HIV vaccine, both completing Phase Ib/II clinical trials.

The name change is effective as of 1st December 2010. In
parallel with this name change, SEEK has launched a new corporate website:

SEEK - A growing and diversifying company

SEEK began life in 2004 as an immunology company, quickly
establishing a new vaccine-technology platform with a focus on peptide-based
T cell vaccines (based on a novel understanding of the molecular level
interactions between immune cells). Lead products under this platform are a
Universal Flu and an HIV vaccine, with Phase Ib/II clinical trial data due
early and mid-2011. Vaccines for mosquito-transported and chagas diseases are
in the pre-clinical phase, with Hepatitis B & C and rotavirus vaccines in

Recent acquisitions have also provided the group with chemical
biology and target-identification expertise. Coupling these competencies with
SEEK's immunology and regulatory knowledge, has resulted in two drugs
entering Phase III clinical trials; one for the treatment of persistent cough
and the second for the treatment of pain, inflammation and auto-immune

Stoloff says: "With our expanding therapeutic focus and
continued successful growth, we felt that now was the time to reposition the
group to ensure our investors, collaborators and partners understand our long
term goals and how we are working to achieve them. "

About SEEK

Founded in 2004, SEEK - previously known as PepTcell - is
privately-owned and funded, with headquarters in London, UK. Using a
pioneering scientific and commercially-driven approach, SEEK aims to create
breakthrough medicines which address major diseases in order to radically
improve human health. SEEK's strategy is to take promising molecules through
the challenging stages of discovery to late-stage human proof-of-principle
and then to seek partners to take the molecules through the final stages of
development and ultimately commercialisation. SEEK's current
product-development areas are vaccines, inflammation/autoimmune diseases,
transplantation tolerance induction, respiratory diseases, cancer and

    For more information about SEEK please contact:

    Gregory Stoloff, Chief Executive Officer Tel +44(0)20-7153-6570

    M: Communications
    Mary-Jane Elliott / Nick Francis / Amber Bielecka Tel +44(0)20-7920-2330

For more information about SEEK please contact: SEEK, Gregory Stoloff, Chief Executive Officer Tel +44(0)20-7153-6570; M: Communications, Mary-Jane Elliott / Nick Francis / Amber Bielecka Tel +44(0)20-7920-2330

will not be displayed